Related Experiment Videos

Aprotinin treatment of pseudomonal corneal infection

J C Stuart1, P T Turgeon, R P Kowalski

  • 1Department of Ophthalmology, University of Pittsburgh, Pennsylvania.

Cornea
|January 1, 1991
PubMed

Insights

Aprotinin, a protease inhibitor, did not improve outcomes for Pseudomonas aeruginosa infected rabbit corneas when added to tobramycin treatment. This study found no added clinical benefit from aprotinin in managing bacterial keratitis.

Area of Science:

  • Ophthalmology
  • Microbiology
  • Pharmacology

Background:

  • Pseudomonas aeruginosa infections can cause severe corneal damage due to proteolytic enzymes.
  • Bacterial keratitis poses a significant threat to vision.

Purpose of the Study:

  • To evaluate the efficacy of aprotinin, a protease inhibitor, in treating P. aeruginosa-induced corneal infections.
  • To determine if aprotinin provides additional clinical benefit when combined with standard antibiotic therapy.

Main Methods:

  • Rabbit corneas were infected with P. aeruginosa.
  • Treatment groups included aprotinin plus tobramycin (topical and subconjunctival) and tobramycin alone.
  • Clinical outcomes were assessed to compare treatment efficacy.

Main Results:

  • Corneas treated with both aprotinin and tobramycin showed no clinical improvement compared to those treated with tobramycin alone.
  • The addition of aprotinin did not mitigate the corneal degradation caused by P. aeruginosa.

Conclusions:

  • Aprotinin is not clinically effective in treating P. aeruginosa keratitis in this rabbit model.
  • Protease inhibition with aprotinin does not offer additional therapeutic benefit beyond standard antibiotic treatment for this condition.

Related Concept Videos